Beovu has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency, Novartis announced in a press release.
An investigational product for the treatment of wet age-related macular degeneration, Beovu (brolucizumab 6 mg) demonstrated noninferiority to aflibercept in the phase 3 HAWK and HARRIER clinical trials. Approximately 30% of patients treated with Beovu in the trials gained at least 15 letters of visual acuity at 1 year, the release said.
“Today’s CHMP opinion brings us another step closer to providing wet AMD patients
Uncategorized